☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2011

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Degarelix (Firmagon®) has been accepted for the treatment of adult male patients with advanced hormone-dependent prostate cancer. The SMC note the benefits of a patient access scheme (PAS) that improves the cost-effectiveness of degarelix and this recommendation is based upon continued access to this scheme.

Valsartan (Diovan®) has been accepted for restricted use in the treatment of hypertension in children and adolescents 6 to 18 years of age provided that treatment is recommended by a paediatric specialist consultant.

Fentanyl nasal spray (PecFent®) has been accepted for restricted use in the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain in patients unsuitable for short-acting oral opioids.

Levetiracetam oral solution (Keppra®) has been restricted use as an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children and infants from 1 month of age to 4 years with epilepsy provided that initiation and management is under the supervision of a paediatric neurologist.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2011' by emailShare 'SMC Update - January 2011' on FacebookShare 'SMC Update - January 2011' on TwitterShare 'SMC Update - January 2011' on LinkedInShare 'SMC Update - January 2011' on reddit


No Comments to “SMC Update - January 2011”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.